Ochsner’s Cardiomyopathy and Heart Transplant Program is the largest Medicare-approved heart transplant program in Louisiana, performing over 20 heart transplants per year.
- First heart transplant in the Gulf South region performed in 1970
Ranked by U.S. News and World Report as one of the 50 best hospitals in America for Heart and Heart Surgery
- Over 800 patients have undergone heart transplant at Ochsner
Interdisciplinary team approach to care consisting of physicians, nurses, pharmacists, nurse practitioners, dieticians, financial coordinators and social workers
Recognizing that heart failure disease requires a multi-faceted approach, our inter-disciplinary team of cardiovascular surgeons, transplant cardiologists, nurse practitioners, physician assistants, transplant coordinators, social workers, financial coordinators, pharmacists and dieticians work together to provide patients a wide array of innovative technologies in the treatment armamentarium for the whole spectrum of heart failure continuum from early stages to end stages of the disease.
We perform state-of-the-art pharmacological, electrophysiological and surgical interventions such as intravenous inotropic and diuretic therapy in our outpatient infusion suite, ultrafiltration (Aquadex) therapy, bi-ventricular pacing, and high risk surgical procedures that includes left ventricular assist devices. Our goal is to provide each patient a tailored plan of treatment addressing their physical, mental and emotional needs with nurse-led clinics, telemanagement, nutrition counseling and social services.
Mechanical Circulatory Support:
Waiting times for a potential donor heart can vary. As a result, our Mechanical Circulatory Support program began in 1990 as a bridge to heart transplantation and destination therapy to extend a patient's formidable years of life.
As one of twenty centers in the REMATCH trial, Ochsner was designated as a "Center for Destination Therapy" for the Heartmate I ventricular assist device (VAD). Since that time, our Cardiovascular Surgeons have participated in research trials for the Jarvik and Micro-med VAD and currently offer the latest technology in the form of the HEARTMATE II LVAD. This device has been used in thousands of patients and is FDA approved as a bridge to transplantation which allows the patient to be discharged home while awaiting transplantation.
When a donor heart is not immediately available, the SynCardia temporary Total Artificial Heart may be an option as a bridge to transplant for patients waiting for a donor heart to become available. The John Ochsner Heart and Vascular Institute is the first in the Gulf South region and one of only 40 certified centers in the U.S. to offer the SynCardia temporary Total Artificial Heart, the world’s first and only FDA-approved total artificial heart.
For More Information and Appointments:
- For patient appointments for Heart Failure and Transplant: (504) 842-4721
- Cardiovascular Services Physician Liaison: Brittany Baker: (504) 418-0959